News

Posted On: 05/04/2005

Genentech Names Vice Presidents in Product Operations and Product Development

PharmaManufacturing.com

Genentech, Inc. (South San Francisco, Calif.) on May 4 announced three vice president appointments in the company's Product Operations and Product Development groups: the promotion of Charles Calderaro to vice president, Corporate Engineering; the appointment of Peter Carberry, M.D., to vice president, Clinical Operations; and the promotion of Todd Rich, M.D., to vice president, Clinical and Commercial Regulatory Affairs.

Chuck Calderaro joined Genentech in 2002 as senior director, Biochemical Manufacturing at the company's Vacaville Product Operations facility. In his new role as vice president, Corporate Engineering, Calderaro will be based in South San Francisco and will lead the development and implementation of engineering projects that support Genentech's growth, including the development of compliant and robust systems, equipment and facilities. Calderaro reports to Patrick Y. Yang, Ph.D., senior vice president, Product Operations and succeeds Timothy L. Moore, who was named vice president, South San Francisco Manufacturing in December 2004.

"Chuck's solid leadership skills and hands-on experience in Engineering, Facilities and Operations make him ideally suited to effecting a strong partnership between Corporate Engineering and the rest of the company in support of our growth," said Yang.

Prior to joining Genentech, Calderaro held leadership roles at Aventis Behring, including director, Biopharmaceutical Manufacturing and, most recently, director, Engineering and Facility Services. Calderaro has also held positions at Alcon Laboratories and Johnson & Johnson's Ethicon division. Calderaro served five years as a Commissioned Naval Officer with the U.S. Navy.

Peter Carberry, M.D., joins Genentech as vice president, Clinical Operations and in this newly created role will be responsible for clinical operational guidance and ensuring the effective execution of all clinical programs. Additionally, he will build and develop the Clinical Operations group, responsible for the creation and sustainability of scalable business processes for clinical trial execution. Carberry reports to Hal Barron, M.D., senior vice president, Development and Chief Medical Officer.

"Peter has a proven track record of successfully managing teams of clinical research professionals and effectively executing clinical trials in the United States as well as globally," said Barron.

Carberry joins Genentech from Johnson & Johnson Pharmaceutical Research and Development, where he served as the senior vice president of Global Operations. Carberry also held several leadership roles in Clinical Development, Corporate Pharmacovigilance and Global Clinical Operations at Pharmacia Corporation.

Todd Rich, M.D., joined Genentech in 1992 as manager, New Product Planning. In 1993, he became senior manager of the newly created Health Economics group. During the next several years, he held positions as director, Product Experience; senior director, Product Development; and, most recently, senior director, Regulatory Affairs.

In the newly created role of vice president, Clinical and Commercial Regulatory Affairs, Rich will be responsible for the regulatory direction of both the Development and Commercial teams, overseeing the regulatory strategy for clinical trials, the management of commercial advertising and promotional materials, and all Food and Drug Administration clinical trial post-marketing commitments. Rich reports to Robert L. Garnick, Ph.D., senior vice president, Regulatory, Quality and Compliance.

"Todd brings to this critical new position strong leadership skills and strategic ability as well as extensive experience in Medical Affairs, Product Development and Regulatory Affairs," said Garnick.

Prior to joining Genentech, Rich was a staff physician in a Level I Trauma Center at St. John Hospital in Detroit.